Lead Product(s) : Cilastatin
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arch Biopartners Announces Health Canada NOL Granted for Phase II PONTiAK Trial
Details : Cilastatin is an enzymatic dipeptidase-1 (DPEP-1) inhibitor, small molecule drug. It is being evaluated for the treatment of toxin related acute kidney injury.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 18, 2025
Lead Product(s) : Cilastatin
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LSALT Peptide
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arch Biopartners Receives Ethics Approval for LSALT Peptide Trial in Acute Kidney Injury
Details : Metablok (LSALT peptide) targets the dipeptidase-1 (DPEP-1) pathway. It is under clinical development for the treatment of cardiac surgery-associated acute kidney injury.
Product Name : Metablok
Product Type : Peptide
Upfront Cash : Inapplicable
January 08, 2025
Lead Product(s) : LSALT Peptide
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cilastatin
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arch Biopartners Discusses Repurposing Cilastatin with FDA for Acute Kidney Injury
Details : Cilastatin is an enzymatic dipeptidase-1 (DPEP-1) inhibitor, small molecule drug. It is being evaluated for the treatment of toxin related acute kidney injury.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2024
Lead Product(s) : Cilastatin
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cilastatin
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arch Biopartners’ Cilastatin to Participate in PONTIAC Trial for Acute Kidney Injury
Details : Cilastatin is an enzymatic dipeptidase-1 (DPEP-1) inhibitor, small molecule drug. It is being evaluated for the treatment of toxin related acute kidney injury.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 08, 2024
Lead Product(s) : Cilastatin
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inversago Pharma Presents Data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress
Details : INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions, including Diabetic Nephropathy.
Product Name : INV-202
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2022
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : INV-202, first-in-class, peripheral CB1 inhibitor, demonstrated efficacy in addressing multiple pathways involved in renal injury also have shown clinical improvements in lipids, weight loss and glucose.
Product Name : INV-202
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2022
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable